NCT00300560

Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli

Efficacy and Safety of Colistin for Therapy of Infections Caused by Extended Spectrum Beta-Lactamase(ESBL) Producing Klebsiella Pneumoniae or Escherichia Coli

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 152 (planned)
• Sponsor: Mahidol University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

In patients with documented ESBL-producing E.coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.

Detailed description

In patients with documented ESBL-producing E.coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.The primary outcome is clinical response and secondary outcomes are microbiological response and adverse events.

Conditions

• Infections

Interventions

Type	Name	Description
DRUG	Colistin

Timeline

• Start date: 2006-02-01
• Completion: 2006-12-01
• First posted: 2006-03-09
• Last updated: 2006-05-22

Locations

1 site across 1 country: Thailand